Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
Phuoc T TranKathryn LoweHua-Ling TsaiDaniel Y SongArthur Y HungJason W D HearnSteven MillerJames A ProudfootMatthew P DeekRyan PhillipsTamara LotanChanning J PallerCatherine Handy MarshallMark C MarkowskiShirl DipasqualeSamuel R DenmeadeMichael CarducciMario A EisenbergerTheodore L DeWeeseMatthew OrtonCurtiland DevilleElai DavicioniStanley L LiauwElisabeth I HeathStephen GrecoNeil B DesaiDaniel E SprattFelix Y FengHao WangTomasz M BeerEmmanuel S AntonarakisPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
SRT plus ENZA monotherapy for 6 months in men with PSA-recurrent high-risk prostate cancer after RP is safe and delays PSA progression relative to SRT alone. The impact of ENZA on distant metastasis or survival is unknown at this time.